Cardiomyopathy — An approach to the autoimmune background

Autoimmunity Reviews

Volumn 16, Issue 3, 2017, Pages 269-286

  Becker, Niels Peter ^a   Müller, Johannes ^a   Göttel, Peter ^a   Wallukat, Gerd ^a   Schimke, Ingolf ^a  

^a Berlin Space Technologies GmbH   (Germany)

Author keywords

Anti beta1 adrenergic receptor autoantibodies; Anti cardiac myosin autoantibodies; Anti cardiac troponin autoantibodies; Anti muscarinic 2 receptor autoantibodies; Autoimmunity; Cardiomyopathy

Indexed keywords

AUTOANTIBODY; CARDIAC MYOSIN; CARDIAC MYOSIN AUTOANTIBODY; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; TROPONIN; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIAC PATIENT; CARDIOMYOPATHY; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; HEART FAILURE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOADSORPTION; IN VIVO STUDY; NONHUMAN; PERIPARTUM CARDIOMYOPATHY; PLASMA EXCHANGE; REVIEW; AUTOIMMUNE DISEASES;

AUTOIMMUNE DISEASES; CARDIOMYOPATHIES; HUMANS;

EID: 85013443444     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.01.012     Document Type: Review

References (240)

1. [1] Wong, F.S., Editorial [Innate and adaptive immune resdponse are highly interconnected of many levels]. Curr Mol Med 9 (2009), 1–3.
2. [2] Wang, L., Wang, F.S., Gershwin, M.E., Human autoimmune diseases: a comprehensive update. J Intern Med 278:4 (2015), 369–395.
3. [3] Floreani, A., Leung, P.S.C., Gershwin, E., Environmental basis of autoimmunity. Clin Rev Allergy Immunol 50 (2016), 287–300.
4. [4] Bordet, J., Sur l'agglutination et le dissolution des globules rouge par le serum d'animaux injectés de sang défibriné. Ann Inst Pasteur 12 (1898), 688–695.
5. [5] Metalnikoff, S., Études sur la spermatoxine. Ann Inst Pasteur 14 (1900), 577–589.
6. [6] Ehrlich, P., Morgenroth, I., Ueber Hämolysine. Fünfte Mitt Berlin Klin Wochenschr 38 (1901), 251–257.
7. [7] Davis, A.M., Gery, I., The role of autoantibodies in heart disease. Am Heart J 60 (1960), 669–674.
8. [8] Cohen, S.G., From immunity to autoimmune disease, a historic trail. Part III. Allergy Asthma Proc 21 (2000), 177–183.
9. [9] Silverstein, A.M., Autoimmunity versus horror autotoxicus: the struggle for recognition. Nat Immunol 2 (2001), 279–281.
10. [10] Donath, J., Landsteiner, K., Uber paroxysmale hamoglobinurie. Münch Med Wochenschr 51 (1904), 1590–1593.
11. [11] Jaffe, R., Holz, F., Experimental allergic myocarditis. Exp Med Surg 6 (1948), 189–202.
12. [12] Saphir, O., Langendorf, R., Nonspecific myocarditis in acute rheumatic fever. Am Heart J 46 (1953), 432–442.
13. [13] Kaplan, M.H., Meyserian, M., Kushner, I., Immunologic studies of heart tissue. IV. Serologic reactions with human heart tissue as revealed by immunofluorescent methods: isoimmune, Wassermann, and autoimmune reactions. J Exp Med 113 (1961), 17–36.
14. [14] Caforio, A.L.P., Tona, F., McKenna, W.J., Organ-specific autoimmunity involvement in cardiovascular diseases. 4. Rheumatic carditis. Doria, A., Pauletto, P., (eds.) Handbook of systemic autoimmune diseases volume 1. The heart in systemic autoimmune diseases, 2004, Elsevier, 23–25.
15. [15] Hess, E.V., Fink, C.W., Taranta, A., Ziff, M., Heart muscle antibodies in rheumatic fever and other dieases. J Clin Invest 43 (1964), 886–893.
16. [16] Jastrzębska, M., Czok, M.E., Guzik, P., Autoimmune diseases, their pharmacological treatment and the cardiovascular system. Cardiol J 20 (2013), 569–576.
17. [17] Caforio, A.L., Marcolongo, R., Jahns, R., Fu, M., Felix, S.B., Iliceto, S., Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management. Heart Fail Rev 18 (2013), 715–732.
18. [18] Satta, N., Vuilleumier, N., Auto-antibodies as possible markers and mediators of ischemic, dilated, and rhythmic cardiopathies. Curr Drug Targets 16:4 (2015), 342–360.
19. [19] Bornholz, B., Wallukat, G., Roggenbuck, D., Schimke, I., Autoantibodies against G-protein-coupled receptors in cardiovascular diseases: basics and diagnostics. Nussinovitch, U., (eds.) The heart in rheumatologic, inflammatory and autoimmune diseases: pathophysiology, clinical aspects and therapeutic approaches, 2017, Elsevier 9780128032671.
20. [20] Fletcher, G.F., Wenger, N.K., Autoimmune studies in patients with primary myocardial disease. Circulation 37 (1968), 1032–1035.
21. [21] Camp, T.F., Hess, E.V., Conway, G., Fowler, N.O., Immunologic findings in idiopathic cardiomyopathy. Am Heart J 77 (1969), 610–618.
22. [22] Das, S.K., Cassidy, J.T., Perry, R.E., Burt, A., Antibodies against nuclear constituents and against heart muscle in cardiomyopathy. Am J Cardiol 25 (1970), 91–92.
23. [23] Kirsner, A.B., Hess, E.V., Fowler, N.O., Immunologic findings in idiopathic cardiomyopathy: a prospective serial study. Am Heart J, 1973, 625–630.
24. [24] Das, S.K., Callen, J.P., Dodson, V.N., Cassidy, J.T., Immunoglobulin binding in cardiomyopathic hearts. Circulation 44 (1971), 612–616.
25. [25] Sanders, V., Ritts, R.E., Ventricular localization of bound gamma globulin in idiopathic disease of the myocardium. JAMA 194 (1965), 59–61.
26. [26] Caforio, A.L., Grazzini, M., Mann, J.M., Keeling, P.J., Bottazzo, G.F., McKenna, W.J., et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 85 (1992), 1734–1742.
27. [27] Ballinas-Vedugo, M.A., Alejandre-Aguilar, R., Aranda-Fraustro, A., Reyes, P.A., Monteon, V.M., Anti-myosin autoantibodies are more frequent in non-chagasic cardiomyopathy than in chagasic cardiomyopathy patients. Int J Cardiol 92 (2003), 101–102.
28. [28] Haghikia, A., Kaya, Z., Schwab, J., Westenfeld, R., Ehlermann, P., Bachelier, K., et al. Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Res Cardiol, 110(6), 2015 Nov, 60, 10.1007/s00395-015-00517-2 [Epub 2015 Oct 30].
29. [29] Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 9 (2003), 1477–1483.
30. [30] Shmilovich, H., Danon, A., Binah, O., Roth, A., Chen, G., Wexler, D., et al. Autoantibodies to cardiac troponin I in patients with idiopathic dilated and ischemic cardiomyopathy. Int J Cardiol 117 (2007), 198–203.
31. [31] Adamczyk, M1., Brashear, R.J., Mattingly, P.G., Circulating cardiac troponin-I autoantibodies in human plasma and serum. Ann N Y Acad Sci 1173 (2009), 67–74.
32. [32] Haberland, A., Wallukat, G., Schimke, I., Aptamer binding and neutralization of β1-adrenoceptor autoantibodies: basics and a vision of its future in cardiomyopathy treatment. Trends Cardiovasc Med 21 (2011), 177–182.
33. [33] Müller, J., Wallukat, G., Schimke, I., Autoantibody directed therapy in cardiovascular diseases. Nussinovitch, U., (eds.) The heart in rheumatologic, inflammatory and autoimmune diseases: pathophysiology, clinical aspects and therapeutic approaches, 2016, Elsevier 9780128032671.
34. [34] Smith, B.R., Pyle, G.A., Petersen, V.B., Hall, R., Interaction of thyroid-stimulating antibodies with the human thyrotrophin receptor. J Endocrinol 75 (1977), 401–407.
35. [35] Cossio, P.M., Diez, C., Szarfman, A., Kreutzer, E., Candiolo, B., Arana, R.M., Chagasic cardiopathy. Demonstration of a serum gamma globulin factor which reacts with endocardium and vascular structures. Circulation 49 (1974), 13–21.
36. [36] Sterin-Borda, L., Cossio, P.M., Gimeno, M.F., Gimeno, A.L., Diez, C., Laguens, R.P., et al. Effect of chagasic sera on the rat isolated atrial preparation: immunological, morphological and function aspects. Cardiovasc Res 10 (1976), 613–622.
37. [37] Borda, E., Pascual, J., Cossio, P., De la Vega, M., Arana, R., Sterin-Borda, L., A circulating IgG in Chagas’ disease which binds to β-adrenoceptors of myocardium and modulates their activity. Clin Exp Immunol 57 (1984), 679–686.
38. [38] Wallukat, G., Wollenberger, A., Effects of gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. Biomed Biochim Acta 46 (1987), S634–S639.
39. [39] Wallukat, G., Muñoz Saravia, S.G., Haberland, A., Bartel, S., Araujo, R., Valda, G., et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas’ cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas’ patients. J Am Coll Cardiol 55 (2010), 463–468.
40. [40] Förster, O.A.E.M., Peripartum cardiomyopathy—an autoimmune disease. Thesis, 2007, Faculty of Health Sciences, University Witwatersrand, Johannesburg [http://wiredspace.wits.ac.za/bitstream/handle/10539/5011/PhD%20Thesis%20final.pdf?sequence=1].
41. [41] Liu, J., Wang, Y., Chen, M., Zhao, W., Wang, X., Wang, H., et al. The correlation between peripartum cardiomyopathy and autoantibodies against cardiovascular receptors. PLoS One, 9(1), Jan 23 2014, e86770, 10.1371/journal.pone.0086770 [eCollection 2014].
42. [42] Wallukat, G., Müller, J., Haberland, A., Berg, S., Schulz, A., Freyse, E.J., et al. Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: a vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies. Atherosclerosis 244 (2016), 44–47.
43. [43] Root-Bernstein, R., Fairweather, D., Unresolved issues in theories of autoimmune disease using myocarditis as a framework. J Theor Biol 375 (2015), 101–123.
44. [44] Castellano, G., Affuso, F., Di Conza, P., Fazio, S., Myocarditis and dilated cardiomyopathy: possible connections and treatments. J Cardiovasc Med (Hagerstown) 9 (2008), 666–671.
45. [45] Caforio, A.L., Tona, F., Bottaro, S., Vinci, A., Dequal, G., Daliento, L., et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 41 (2008), 35–45.
46. [46] Xu, X., Jiang, Y., The Yin and Yang of innate immunity in stroke. Biomed Res Int 2014 (2014), 807–978.
47. [47] van der Laan, A.M., Nahrendorf, M., Piek, J.J., Healing and adverse remodelling after acute myocardial infarction: role of the cellular immune response. Heart 98 (2012), 1384–1390.
48. [48] Lukitsch, I., Kehr, J., Chaykovska, L., Wallukat, G., Nieminen-Kelhä, M., Batuman, V., et al. Renal ischemia and transplantation predicts pose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 94 (2012), 8–13.
49. [49] Wallukat, G., Wollenberger, A., Involvement of β2-adrenergic receptors in the potentaion of the chronotropic action of isoprenaline evoked in rocker-cultured neonatal rat heart cells by pyruvate and L (+) lactate. Beamisch, R.E., Panagia, V., Dhalla, N.S., (eds.) Pharmacological aspects of heart disease, 1987, Martinius Nijhoff Publishing, Boston, 217–231.
50. [50] Munoz-Saravia, S.G., Haberland, A., Wallukat, G., Schimke, I., Chronic Chagas’ heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine. Heart Fail Rev 17 (2012), 45–64.
51. [51] Eftekhari, P., Sallé, L., Lezoualc'h, F., Mialet, J., Gastineau, M., Briand, J.P., et al. Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol 30 (2000), 2782–2790.
52. [52] Kamel, R., Eftekhari, P., Clancy, R., Buyon, J.P., Hoebeke, J., Autoantibodies against the serotoninergic 5HT4 receptor and congenital heart block. J Autoimmun 25 (2005), 72–76.
53. [53] Ciháková, D., Sharma, R.B., Fairweather, D., Afanasyeva, M., Rose, N.R., Animal models for autoimmune myocarditis and autoimmune thyroiditis. Methods Mol Med 102 (2004), 175–193.
54. [54] Spotnitz, M.D., Lesch, M., Idiopathic dilated cardiomyopathy as a late complication of healed viral (Coxsackie B virus) myocarditis: historical analysis, review of the literature, and a postulated unifying hypothesis. Prog Cardiovasc Dis 49 (2006), 42–57.
55. [55] Matsumoto, Y., Park, I.K., Kohyama, K., B-cell epitope spreading is a critical step for the switch from C-protein-induced myocarditis to dilated cardiomyopathy. Am J Pathol 170 (2007), 43–51.
56. [56] Paque, R.E., Miller, R., Adoptively transferred anti-idiotype pulsed B cells mediate autoimmune myocarditis. Infect Immun 60 (1992), 3396–3404.
57. [57] Root-Bernstein, R., Couturier, J., Antigenic complementarity in the origins of autoimmunity: a general theory illustrated with a case study of idiopathic thrombocytopenia purpura. Clin Dev Immunol 13 (2006), 49–65.
58. [58] Caforio, A.L., Vinci, A., Iliceto, S., Anti-heart autoantibodies in familial dilated cardiomyopathy. Autoimmunity 41 (2008), 462–469.
59. [59] Lappé, J.M., Pelfrey, C.M., Tang, W.H., Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy. J Card Fail 14 (2008), 521–530.
60. [60] Nussinovitch, U., Shoenfeld, Y., Anti-troponin autoantibodies and the cardiovascular system. Heart 96 (2010), 1518–1524.
61. [61] Kaya, Z., Katus, H.A., Rose, N.R., Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure. Clin Immunol 134 (2010), 80–88.
62. [62] Nussinovitch, U., Shoenfeld, Y., The diagnostic and clinical significance of anti-muscarinic receptor autoantibodies. Clin Rev Allergy Immunol 42 (2012), 298–308.
63. [63] Nussinovitch, U., Shoenfeld, Y., The clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease. Clin Rev Allergy Immunol 44 (2013), 75–83.
64. [64] Nussinovitch, U., Shoenfeld, Y., The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease. Clin Rev Allergy Immunol 44 (2013), 98–108.
65. [65] Neu, N., Rose, N.R., Beisel, K.W., Herskowitz, A., Gurri-Glass, G., Craig, S.W., Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 139 (1987), 3630–3636.
66. [66] Smith, S.C1., Allen, P.M., Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol 147 (1991), 2141–2147.
67. [67] Pummerer, C.L., Luze, K., Grässl, G., Bachmaier, K., Offner, F., Burrell, S.K., et al. Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. J Clin Invest 97 (1996), 2057–2062.
68. [68] Nunes, D.F., Guedes, P.M., Andrade Cde, M., Câmara, A.C., Chiari, E., Galvão, L.M., Troponin T autoantibodies correlate with chronic cardiomyopathy in human Chagas disease. Trop Med Int Health 18 (2013), 1180–1192.
69. [69] Madaio, M.P., Yanase, K., Foster, M.H., Smith, R.M., Emmons, T.K., Fabbi, M., et al. Nuclear localization of autoantibodies. Novel insights into protein translocation and cellular function. Ann N Y Acad Sci 815 (1997), 263–266.
70. [70] Yanase, K., Smith, R.M., Puccetti, A., Jarett, L., Madaio, M.P., Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 100 (1997), 25–31.
71. [71] Warraich, R.S., Griffiths, E., Falconar, A., Pabbathi, V., Bell, C., Angelini, G., et al. Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship. FASEB J 20 (2006), 651–660.
72. [72] Liao, L., Sindhwani, R., Rojkind, M., Factor, S., Leinwand, L., Diamond, B., Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med 181 (1995), 1123–1131.
73. [73] Léger, J.O., Larue, C., Ming, T., Calzolari, C., Gautier, P., Mouton, C., et al. Assay of serum cardiac myosin heavy chain fragments in patients with acute myocardial infarction: determination of infarct size and long-term follow-up. Am Heart J 120 (1990), 781–790.
74. [74] Zhang, P., Cox, C.J., Alvarez, K.M., Cunningham, M.W., Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol 183 (2009), 27–31.
75. [75] Galvin, J.E., Hemric, M.E., Ward, K., Cunningham, M.W., Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest 106 (2000), 217–224.
76. [76] Li, Y., Heuser, J.S., Cunningham, L.C., Kosanke, S.D., Cunningham, M.W., Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 177 (2006), 8234–8240.
77. [77] Yu, X., Lindenfeld, J., Olansky, L., Lyons, T., Duvall, D., Heuser, J.S., et al. Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity 41 (2008), 442–453.
78. [78] Bohner, J., von Pape, K.W., Hannes, W., Stegmann, T., False-negative immunoassay results for cardiac troponin I probably due to circulating troponin I autoantibodies. Clin Chem, 42, 1996, 2046.
79. [79] Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:5502 (2001), 319–322.
80. [80] Göser, S., Andrassy, M., Buss, S.J., Leuschner, F., Volz, C.H., Ottl, R., et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 114 (2006), 1693–1702.
81. [81] Leuschner, F., Li, J., Göser, S., Reinhardt, L., Ottl, R., Bride, P., et al. Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction. Eur Heart J 29 (2008), 1949–1955.
82. [82] Kaya, Z., Göser, S., Buss, S.J., Leuschner, F., Ottl, R., Li, J., et al. Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation 11:118 (2008), 2063–2372.
83. [83] Wallukat, G., Morwinski, M., Kowal, K., Förster, A., Boewer, V., Wollenberger, A., Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: beta-adrenergic agonism without desensitization. Eur Heart J 12:Suppl. D (1991), 178–181.
84. [84] Wallukat, G., Schimke, I., Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol 36 (2014), 351–363.
85. [85] Munoz-Saravia, S.G., Haberland, A., Wallukat, G., Schimke, I., Chronic Chagas’ heart disease — from pathogenesis to treatment regimes. Appl Cardiopulm Pathophysiol 16 (2012), 55–81.
86. [86] Limas, C.J., Goldenberg, I.F., Limas, C., Influence of anti-beta receptor antibodies on cardiac adenylate cyclase in patients with idiopathic dilated cardiomyopathy. Am Heart J 119 (1990), 1322–1328.
87. [87] Jahns, R., Boivin, V., Lohse, M.J., Beta1-adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int J Cardiol, 112, 2006, 7-4.
88. [88] Xia, Y., Wen, H., Bobst, S., Day, M.C., Kellems, R.E., Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig 10 (2003), 82–93.
89. [89] Wallukat, G., Wolleberger, A., Autoantibodies to β2 adrenergic receptor with antiadrenergic activity from patients with allergic asthma. J Allergy Clin Immunol 88 (1991), 581–587.
90. [90] Mijares, A., Lebesgue, D., Argibay, J., Hoebeke, J., Anti-peptide antibodies sensitive to the active state of the beta2 adrenergic receptor. FEBS Lett 399 (1996), 188–191.
91. [91] Elies, R., Fu, L.X.M., Eftekhari, P., Wallukat, G., et al. Immunochemical and functional characterization of an agonist-like monoclonal antibody against the M2 acetylcholine receptor. Eur J Biochem 251 (1998), 659–666.
92. [92] Mijares, A., Lesbesgue, D., Wallukat, G., Hoebeke, J., From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-β(2)-adrenoceptor antibody behave as antagonist. Mol Pharmacol 58 (2000), 373–379.
93. [93] Hoebeke, J., Molecular mechanisms of anti-G-protein-coupled receptor autoantibody. Autoimmunity 34 (2001), 161–164.
94. [94] Elias, F., Detection of Trypanosoma cruzi DNA and analysis of the B cell in the heart tissue of patients with chronic Chagas’ heart disease. Dissertation, 2001, FU, Berlin.
95. [95] Wallukat, G., Fu, M.L.X., Magnusson, Y., Hjalmarson, Ǻ., Hoebeke, J., Wollenberger, A., Agonistic effects of anti-peptide antibodies and autoantibodies against adrenergic and cholinergic receptors: absence of desensitisation. Blood Press 5 (1996), 31–36.
96. [96] Jahns, R., Boivin, V., Krapf, T., Wallukat, G., Boege, F., Lohse, M.J., Modulation of β1-adrenoceptor activity by domain-specific antibodies and heart-failure associated autoantibodies. J Am Coll Cardiol 36 (2000), 1280–1287.
97. [97] Krause, E.G., Bartel, S., Beyerdörfer, I., Wallukat, G., Activation of cyclic AMP-dependent protein kinase in cardiomyocytes by anti-beta 1-adrenoceptor autoantibodies from patients with idiopathic dilated cardiomyopathy. Blood Press(Suppl. 3), 1996, 37–40.
98. [98] Christ, T., Wetwer, E., Dobrew, D., Adolph, E., Knaut, M., Wallukat, G., et al. Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 33 (2001), 1280–1287.
99. [99] Wang, L., Lu, K., Hao, H., Li, X., Wang, J., Wang, K., et al. Decreased autophagy in rat heart induced by anti-β1-adrenergic receptor autoantibodies contributes to the decline in mitochondrial membrane potential. PLoS One, 8, 2013, e81296.
100. [100] Staudt, Y., Mobini, R., Fu, M., Felix, S.B., Kuhn, J.P., Staudt, A., Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol 466 (2003), 1–6.
101. [101] Jane-wit, D., Alfuntas, C.Z., Johnson, J.M., Yong, S., Wickley, P.J., Wang, C., et al. Beta1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 116 (2007), 399–410.
102. [102] Haberland, A., Wallukat, G., Dahmen, C., Kage, A., Schimke, I., Aptamer neutralization of beta1-adrenoceptror autoantibodies isolated from patients with cardiomyopathies. Circ Res 109 (2011), 986–992.
103. [103] Okruhlikova, L., Morwinski, R., Schulze, W., Bartel, S., Weismann, P., Tribulova, N., et al. Autoantibodies against G-protein coupled receptors modulate heart mast cells. Cell Mol Immunol 4 (2007), 127–133.
104. [104] Tutor, A.S., Penela, P., Mayor, F. Jr., Anti-beta1-adrenergic receptor autoantibodies are potent stimulators of the ERK1/2 pathway in cardiac cells. Cardiovasc Res 76 (2007), 51–60.
105. [105] Du, Y., Yan, L., Wang, J., Zhan, W., Song, K., Han, X., et al. β1-Adrenoceptor autoantibodies from DCM patients enhance the proliferation of T lymphocytes through the β1-AR/cAMP/PKA and p38 MAPK pathways. PLoS One, 7, 2012, e52911.
106. [106] Wallukat, G., Fu, H.M., Matsui, S., Hjalmarson, Å., Fu, M.L., Autoantibodies against M2 muscarinic receptors in patients with cardiomyopathy display non-desensitizing agonist-like effects. Life Sci 64 (1999), 465–469.
107. [107] Goin, J.C., Leiros, C.P., Sterin-Borda, L., Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 11 (1997), 77–83.
108. [108] Lazzerini, P.E., Capecchi, P.L., Guideri, F., Acampa, M., Selvi, E., Bisogno, S., et al. Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications. Basic Res Cardiol 103 (2008), 1–11.
109. [109] Hong, C.M1., Zheng, Q.S., Liu, X.T., Shang, F.J., Wang, H.T., Jiang, W.R., Effects of autoantibodies against M2 muscarinic acetylcholine receptors on rabbit atria in vivo. Cardiology 112 (2009), 180–187.
110. [110] Dobrev, D., Christ, T., Ravens, U., Muscarinic subtype-2 receptor autoantibodies: actors or bystanders in human atrial fibrillation?. Eur Heart J 25 (2004), 1091–1092.
111. [111] Ganzinelli, S1., Borda, E., Joensen, L., Sterin-Borda, L., Chagasic antibodies induce cardiac COX-2/iNOS mRNA expression with PGE2/NO production. Int J Cardiol 134 (2009), 212–223.
112. [112] Matsui, S., Fu, M.L.X., Katsuda, S., Hayase, M., Yamaguchi, N., Teraoka, K., et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 29 (1997), 641–655.
113. [113] Matsui, S., Fu, M.L., Hayase, M., Katsuda, S., Yamaguchi, N., Teraoka, K., et al. Active immunization of combined beta1-adrenoceptor and M2-muscarinic receptor peptides induces cardiac hypertrophy in rabbits. J Card Fail 5 (1999), 246–254.
114. [114] Jahns, R., Boivin, V., Hein, L., Triebel, S., Angermann, C.E., Ertl, G., et al. Direct evidence for a beta1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113 (2004), 1419–1429.
115. [115] Matsui, S., Fu, M., Hayase, M., Katsuda, S., Yamaguchi, N., Teraoka, K., et al. Transfer of rabbit autoimmune cardiomyopathy into severe combined immunodeficiency mice. J Cardiovasc Pharmacol 42:Suppl. 1 (2003), 99–103.
116. [116] Omerovic, E., Bollano, E., Andersson, B., Kujacic, V., Schulze, W., Hjalmarson, Å., et al. (2000) Induction of cardiomyopathy in severe combined immunodeficiency mice by transfer of lymphocytes from patients with idiopathic dilated cardiomyopathy. Autoimmunity 32 (2000), 271–280.
117. [117] Li, H., Scherlag, B.J., Kem, D.C., Benbrook, A., Shen, X., Cunningham, M.W., et al. Inducible cardiac arrhythmias caused by enhanced β1-adrenergic autoantibody expression in the rabbit. Am J Physiol Heart Circ Physiol 306 (2014), H422–H428.
118. [118] Cunha-Neto, E., Teixeira, P.C., Nogueira, L.G., Kalil, J., Autoimmunity. Adv Parasitol 76 (2011), 129–152.
119. [119] Teixeira, A.R., Santos-Buch, C.A., The immunology of experimental Chagas’ disease. I. Preparation of Trypanosoma cruzi antigens and humoral antibody response to their antigens. J Immunol 113 (1974), 859–869.
120. [120] Acosta, A.M., Santos-Buch, C.A., Autoimmune myocarditis induced by Trypanosoma cruzi. Circulation 71 (1985), 1255–1261.
121. [121] Retondaro, F.C., Dos Santos Costa, P.C., Pedrosa, R.C., Kurtenbach, E., Presence of antibodies against the third intracellular loop of the m2 muscarinic receptor in the sera of chronic chagasic patients. FASEB J 13 (1999), 2015–2020.
122. [122] Sundstrom, J.B., Fett, J.D., Carraway, R.D., Ansari, A.A., Is peripartum cardiomyopathy an organ-specific autoimmune disease?. Autoimmun Rev 1 (2002), 73–77.
123. [123] Fett, J.D., Peripartum cardiomyopathy: a puzzle closer to solution. World J Cardiol 6 (2014), 87–99.
124. [124] Wallukat, G., Morwinski, R., Magnusson, Y., Hoebeke, J., Wollenberger, A., Autoantibodies against the beta 1-adrenergic receptor in myocarditis and dilated cardiomyopathy: localization of two epitopes. Z Kardiol 81:Suppl. 4 (1992), 79–83.
125. [125] Chiale, P.A., Rosenbaum, M.B., Elizari, M.V., Hjalmarson, Å., Magnusson, Y., Wallukat, G., et al. High prevalence of antibodies against beta1- and beta2-adrenoceptors in patients with primary electrical abnormalities. J Am Coll Cardiol 26 (1995), 864–869.
126. [126] Brisinda, D., Sorbo, A.R., Venuti, A., Ruggieri, M.P., Manna, R., Fenici, P., et al. Anti-β-adrenoceptor autoimmunity causing idiopathic arrhythmias and cardiomyopathy. Circ J 76 (2012), 1345–1353.
127. [127] Iwata, M., Yoshikawa, T., Baba, A., Anzai, T., Mitamura, H., Ogawa, S., Autoantibodies against the second extracellular loop of the β1-adrenergic receptor predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 37 (2001), 418–424.
128. [128] Wallukat, G., Müller, J., Hetzer, R., Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med, 347, 2002, 1806.
129. [129] Schimke, I., Müller, J., Dandel, M., Gremmels, H.D., Bayer, W., Wallukat, B., et al. Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti-beta 1-adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study. J Clin Apher 20 (2005), 137–142.
130. [130] Dandel, M., Wallukat, G., Englert, A., Lehmkuhl, H.B., Knosalla, C., Hetzer, R., Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail 14 (2012), 1374–1388.
131. [131] Karczewski, P., Hempel, P., Kunze, R., Bimmler, M., Agonistic autoantibodies to the α(1)-adrenergic receptor and the β(2)-adrenergic receptor in Alzheimer's and vascular dementia. Scand J Immunol 75 (2012), 524–530.
132. [132] Hempel, P., Heinig, B., Jerosch, C., Decius, I., Karczewski, P., Kassner, U., et al. Immunoadsorption of agonistic autoantibodies against α1-adrenergic receptors in patients with mild to moderate dementia. Ther Apher Dial, Apr 20 2016, 10.1111/1744-9987.12415 [Epub ahead of print].
133. [133] Loebel, M., Grabowski, P., Heidecke, H., Bauer, S., Hanitsch, L.G., Wittke, K., et al. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain Behav Immun 52 (2016), 32–39.
134. [134] Ikeda, S1., Neurologic complications in HPV vaccination. Brain Nerve 67 (2015), 835–843.
135. [135] Hendrickson, J.E., Tormey, C.A., Human papilloma virus vaccination and dysautonomia: considerations for autoantibody evaluation and HLA typing. Vaccine, 34, 2016, 4468.
136. [136] Liu, H.R., Zhao, R.R., Zhi, J.M., Wu, B.W., Fu, M.L., Screening of serum autoantibodies to cardiac beta1-adrenoceptors and M2-muscarinic acetylcholine receptors in 408 healthy subjects of varying ages. Autoimmunity 29 (1999), 43–51.
137. [137] Dilated cardiomyopathy pathology. Author Allen Patrick Burke. Reference to a website: http://emedicine.medscape.com/article/2017823-overview.
138. [138] Hershberger, R.E., Hedges, D.J., Morales, A., Dilated cardiomyopathy: the compexity of a diverse genetic architecture. Nat Rev Cardiol, 2013, 531–547.
139. [139] Konstadoulakis, M.M., Kroumbouzou, H., Tsiamis, E., Trikas, A., Toutouzas, P., Clinical significance of antibodies against tropomyosin, actin and myosin in patients with dilated cardiomyopathy. J Clin Lab Immunol 40 (1993), 61–67.
140. [140] Goldman, J.H., Keeling, P.J., Warraich, R.S., Baig, M.K., Redwood, S.R., Dalla Libera, L., et al. Autoimmunity to alpha myosin in a subset of patients with idiopathic dilated cardiomyopathy. Br Heart J 74 (1995), 598–603.
141. [141] Caforio, A.L1., Goldman, J.H., Baig, M.K., Dalla Libera, L., Keeling, P.J., McKenna, W.J., Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression. Heart 77 (1997), 62–67.
142. [142] Warraich, R.S., Dunn, M.J., Yacoub, M.H., Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: pro-inflammatory antibodies in DCM patients. Biochem Biophys Res Commun 259 (1999), 255–261.
143. [143] Warraich, R.S., Noutsias, M., Kazak, I., Seeberg, B., Dunn, M.J., Schultheiss, H.P., et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J 143 (2002), 1076–1084.
144. [144] Pang, H., Liao, Y., Wang, Z., Dong, J., Lu, Q., Effect of anti-cardiac myosin antibody on prognosis of patients with acute myocardial infarction. J Tongji Med Univ 20 (2000), 46–48.
145. [145] Miettinen, K.H., Eriksson, S., Magga, J., Tuomainen, P., Kuusisto, J., Vanninen, E.J., et al. Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy. J Card Fail 14 (2008), 481–488.
146. [146] Landsberger, M., Staudt, A., Choudhury, S., Trimpert, C., Herda, L.R., Klingel, K., et al. Potential role of antibodies against cardiac Kv channel-interacting protein 2 in dilated cardiomyopathy. Am Heart J 156 (2008), 92–99.
147. [147] Wallukat, G., Nissen, E., Morwinski, R., Müller, J., Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz 25 (2000), 261–266.
148. [148] Wallukat, G., Wollenberger, A., Morwinski, R., Pitschner, H.F., Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 27 (1995), 397–406.
149. [149] Nikolaev, V.O., Boivin, V., Störk, S., Angermann, C.E., Ertl, G., Lohse, M.J., et al. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol 50 (2007), 423–431.
150. [150] Störk, S., Boivin, V., Horf, R., Hein, L., Lohse, M.J., Angermann, C.E., et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 152 (2006), 697–704.
151. [151] Fu, M.L., Hoebeke, J., Matsui, S., Matoba, M., Magnusson, Y., Hedner, T., et al. Autoantibodies against cardiac G-protein-coupled receptors define different populations with cardiomyopathies but not with hypertension. Clin Immunol Immunopathol 72 (1994), 15–20.
152. [152] Holthoff, H.P., Zeibig, S., Jahns-Boivin, V., Bauer, J., Lohse, M.J., Kääb, S., et al. Detection of anti-β1-AR autoantibodies in heart failure by a cell-based competition ELISA. Circ Res 111 (2012), 675–684.
153. [153] Jahns, R., Boivin, V., Siegmund, C., Inselmann, G., Lohse, M.J., Boege, F., Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 99 (1999), 649–654.
154. [154] Nagatomo, Y., Yoshikawa, T., Kohno, T., Yoshizawa, A., Baba, A., Anzai, T., et al. A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. J Card Fail 15 (2009), 224–232.
155. [155] Reinthaler, M., Empen, K., Herda, L.R., Schwabe, A., Rühl, M., Dörr, M., et al. The effect of a repeated immunoadsorption in patients with dilated cardiomyopathy after recurrence of severe heart failure symptoms. J Clin Apher 30 (2015), 217–223.
156. [156] Müller, J., Wallukat, G., Dandel, M., Bieda, H., Brandes, K., Spiegelsberger, S., et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 101 (2000), 385–391.
157. [157] Zhang, L., Hu, D., Li, J., Wu, Y., Liu, X., Yang, X., Autoantibodies against the myocardial beta1-adrenergic and M2-muscarinic receptors in patients with congestive heart failure. Chin Med J (Engl) 115 (2002), 1127–1131.
158. [158] Ferrari, I, Levin, M.J., Wallukat, G., Elies, R., Lebesgue, D., Chiale, P., et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med 182 (1995), 59–65.
159. [159] Lee, H.C., Huang, K.T., Wang, X.L., Shen, W.K., Autoantibodies and cardiac arrhythmias. Heart Rhythm 8 (2011), 1788–1795.
160. [160] Definition of Chagas disease. http://www.medicinenet.com/script/main/art.asp?articlekey=23102.
161. [161] World Health Organization, Chagas disease (American trypanosomiasis). March 2016, WHO Available at http://www.who.int/mediacentre/factsheets/fs340/en/. [Accessed: July 17, 2016].
162. [162] Talvani, A., Rocha, M.O., Ribeiro, A.L., Borda, E., Sterin-Borda, L., Teixeira, M.M., Levels of anti-M2 and anti-beta1 autoantibodies do not correlate with the degree of heart dysfunction in Chagas’ heart disease. Microbes Infect 8 (2006), 2459–2464.
163. [163] Levin, M.J., Hoebeke, J., Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas’ heart disease. Autoimmunity 41 (2008), 429–433.
164. [164] Peripartum Cardiomyopathy. Author Michael P Carson and Coauthor David Evan Jacob. http://emedicine.medscape.com/article/153153-overview.
165. [165] Midei, M.G., DeMent, S.H., Feldman, A.M., Hutchins, G.M., Baughman, K.L., Peripartum myocarditis and cardiomyopathy. Circulation 81:3 (1990), 922–928 [1 März].
166. [166] Felker, G.M., Thompson, R.E., Hare, J.M., Hruban, R.H., Clemetson, D.E., Howard, D.L., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 (2000), 1077–1084.
167. [167] Warraich, R.S., Sliwa, K., Damasceno, A., Carraway, R., Sundrom, B., Arif, G., et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cardiomyopathy. Am Heart J 150 (2005), 263–269.
168. [168] Nussinovitch, U., Shoenfeld, Y., Autoimmunity and heart diseases: pathogenesis and diagnostic criteria. Arch Immunol Ther Exp (Warsz) 57 (2009), 95–104.
169. [169] Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee, http://www.transfusionguidelines.org.uk/transfusion-handbook/11-therapeutic-apheresis/11-1-therapeutic-plasma-exchange-tpe.
170. [170] Gesinde, M.O., Tan, L.B., Gooi, H.C., Plasma exchange treatment to reduce anti-beta1-adrenergic receptor antibody in a patient with dilated cardiomyopathy. J Clin Apher 22 (2007), 241–242.
171. [171] Sugiyama, H., Hoshiai, M., Sugita, K., Matsuda, K., Plasma exchange for removal of antibeta1-adrenergic receptor antibody in a small child with dilated cardiomyopathy. Pediatr Cardiol 30 (2009), 374–376.
172. [172] Torre-Amione, G., Orrego, C.M., Khalil, N., Kottner-Assad, C., Leveque, C., Celis, R., et al. Therapeutic plasma exchange a potential strategy for patients with advanced heart failure. J Clin Apher 25 (2010), 323–330.
173. [173] Koizumi, K., Hoshiai, M., Toda, T., Katsumata, N., Kise, H., Hasebe, Y., et al. Outcomes of plasma exchange for severe dilated cardiomyopathy in children. Heart Vessels, Apr 27 2016 [Epub ahead of print].
174. [174] Wang, T.L., Hung, H.F., Shyu, K.G., Yeh, J.H., Chiu, H.C., Successful treatment of peripartum cardiomyopathy with plasmapheresis. Acta Cardiol Sin 29 (2013), 471–474.
175. [175] Łasińska-Kowaraa, M., Lango, R., Kowalik, M., Jarmoszewicz, K., Accelerated heart function recovery after therapeutic plasma exchange in patient treated with biventricular mechanical circulatory support for severe peripartum cardiomyopathy. Eur J Cardiothorac Surg 46 (2014), 1035–1036.
176. [176] Fresenius Medical Care, Apheresis therapy systems. Immunoadsorption. http://www.fmc.nl/media/1129/ia_brochure_algemeen_01_14_gb_w.pdf.
177. [177] Wallukat, G., Reinke, P., Dörffel, W.V., Luther, H.P., Bestvater, K., Felix, S.B., et al. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 54 (1996), 191–195.
178. [178] Dorffel, W.V., Felix, S.B., Wallukat, G., Brehme, S., Bestvater, K., Hofmann, T., et al. Short-term hemodynamic effect of immunoadsorption in dilated cardiomyopathy. Circulation 95 (1997), 1994–1997.
179. [179] Cooper, L.T., Belohlavek, M., Korinek, J., Yoshifuku, S., Sengupta, P.P., Burgstaler, E.A., et al. A pilot study to assess the use of protein A immunoadsorption for chronic dilated cardiomyopathy. J Clin Apher 224 (2007), 210–214.
180. [180] Felix, S.B., Staudt, A., Dorffel, W.V., Stangl, V., Merkel, K., Pohl, M., et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 35 (2000), 1590–1598.
181. [181] Felix, S.B., Staudt, A., Landsberger, M., Grosse, Y., Stangl, V., Spielhagen, T., et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 20:39 (2002), 646–652.
182. [182] Mobini, R., Staudt, A., Felix, S.B., Baumann, G., Wallukat, G., Deinum, J., et al. Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 20 (2003), 345–350.
183. [183] Dörffel, W.V., Wallukat, G., Dörffel, Y., Felix, S.B., Baumann, G., Immunoadsorption in idiopathic dilated cardiomyopathy, a 3-year follow-up. Int J Cardiol 97 (2004), 529–534.
184. [184] Knebel, F., Böhm, M., Staudt, A., Borges, A.C., Tepper, M., Jochmann, N., et al. Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. Int J Cardiol 97 (2004), 517–520.
185. [185] Baba, A., Akaishi, M., Shimada, M., Monkawa, T., Wakabayashi, Y., Takahashi, M., et al. Complete elimination of cardiodepressant IgG3 autoantibodies by immunoadsorption in patients with severe heart failure. Circ J 74 (2010), 1372–1378.
186. [186] Burgstaler, E.A., Cooper, L.T., Winters, J.L., Treatment of chronic dilated cardiomyopathy with immunoadsorption using the staphylococcal A-agarose column: a comparison of immunoglobulin reduction using two different techniques. J Clin Apher 22 (2007), 224–232.
187. [187] Schimke, I., Müller, J., Priem, F., Kruse, I., Schön, B., Stein, J., et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 38 (2001), 178–183.
188. [188] Staudt, A., Hummel, A., Ruppert, J., Dörr, M., Trimpert, C., Birkenmeier, K., et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J, 152, 2006 [712.e1–6].
189. [189] Staudt, A., Staudt, Y., Hummel, A., Empen, K., Dörr, M., Trimpert, C., et al. Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy. Ther Apher Dial 10 (2006), 42–48.
190. [190] Herda, L.R., Trimpert, C., Nauke, U., Landsberger, M., Hummel, A., Beug, D., et al. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy. Am Heart J 159 (2010), 809–816.
191. [191] Bulut, D., Scheeler, M., Wichmann, T., Börgel, J., Miebach, T., Mügge, A., Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy. Clin Res Cardiol 99 (2010), 633–638.
192. [192] Bulut, D., Scheeler, M., Niedballa, L.M., Miebach, T., Mügge, A., Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy. Clin Res Cardiol 100 (2011), 603–610.
193. [193] Bulut, D., Creutzenberg, G., Mügge, A., The number of regulatory T cells correlates with hemodynamic improvement in patients with inflammatory dilated cardiomyopathy after immunoadsorption therapy. Scand J Immunol 77 (2013), 54–61.
194. [194] Doesch, A.O., Konstandin, M., Celik, S., Kristen, A., Frankenstein, L., Hardt, S., et al. (2009). Effects of protein A immunoadsorption in patients with advanced chronic dilated cardiomyopathy. J Clin Apher 24 (2009), 141–149.
195. [195] Doesch, A.O., Mueller, S., Konstandin, M., Celik, S., Kristen, A., Frankenstein, L., et al. Effects of protein A immunoadsorption in patients with chronic dilated cardiomyopathy. J Clin Apher 25 (2010), 315–322.
196. [196] Trimpert, C., Herda, L.R., Eckerle, L.G., Pohle, S., Müller, C., Landsberger, M., et al. Immunoadsorption in dilated cardiomyopathy: long-term reduction of cardiodepressant antibodies. Eur J Clin Invest 40 (2010), 685–691.
197. [197] Ameling, S., Bhardwaj, G., Hammer, E., Beug, D., Steil, L., Reinke, Y., et al. Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution. Basic Res Cardiol, 111, 2016, 53, 10.1007/s00395-016-0569-y [Epub 2016 Jul 13].
198. [198] Dandel, M., Englert, A., Wallukat, G., Riese, A., Knosalla, C., Stein, J., et al. Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus. Atheroscler Suppl 18 (2015), 124–133.
199. [199] Hempel, P., Karczewski, P., Kohnert, K.D., Raabe, J., Lemke, B., Kunze, R., et al. Sera of patients with type2 diabetes contains agonistic autoantibodies against G-protein coupled receptors. Scand J Immunol 70 (2009), 159–160.
200. [200] Nagatomo, Y., Baba, A., Ito, H., Naito, K., Yoshizawa, A., Kurita, Y., et al. Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy. J Clin Apher 26 (2011), 1–8.
201. [201] Yoshikawa, T., Baba, A., Akaishi, M., Wakabayashi, Y., Monkawa, T., Kitakaze, M., et al. Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column-A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety. J Clin Apher, 2016, 10.1002/jca.21446 [Epub ahead of print].
202. [202] Pokrovsky, S.N., Ezhov, M.V., Safarova, M.S., Saidova, M.A., Shitov, V.N., Afanasieva, M.I., et al. Ig apheresis for the treatment of severe DCM patients. Atheroscler Suppl 14 (2013), 213–218.
203. [203] Labovsky, V., Smulski, C.R., Gómez, K., Levy, G., Levin, M.J., (2007). Anti-beta1-adrenergic receptor autoantibodies in patients with chronic Chagas heart disease. Clin Exp Immunol 148 (2007), 440–449.
204. [204] Wallukat, G., Haberland, A., Schimke, I., A vision of future treatment in chagas heart disease. J Am Coll Cardiol, 63, 2014, 1027.
205. [205] Fett, J.D., Understanding peripartum cardiomyopathy, 2008. Int J Cardiol 130 (2008), 1–2.
206. [206] Sliwa, K., Fett, J., Elkayam, U., Peripartum cardiomyopathy. Lancet 368 (2006), 687–693.
207. [207] Hessel, F.P., Wegner, C., Müller, J., Glaveris, C., Wasem, J., Economic evaluation and survival analysis of immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Eur J Health Econ 5 (2004), 58–63.
208. [208] Haberland, A., Wallukat, G., Schimke, I., The patent situation concerning the treatment of diseases associated with autoantibodies directed against G-protein-coupled receptors. Pharm Pat Anal 2 (2013), 231–248.
209. [209] Kaveri, S.V., Lecerf, M., Saha, C., Kazatchkine, M.D., Lacroix-Desmazes, S., Bayry, J., Intravenous immunoglobulin and immune response. Clin Exp Immunol 178:Suppl. 1 (2014), 94–96.
210. [210] Dalakas, M.C., Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59:Suppl. 6 (2002), S13–S21.
211. [211] Aukrust, P., Yndestad, A., Ueland, T., Damås, J.K., Frøland, S.S., Gullestad, L., The role of intravenous immunoglobulin in the treatment of chronic heart failure. Int J Cardiol 112 (2006), 40–45.
212. [212] Nussinovitch, U., Shoenfeld, Y., Intravenous immunoglobulin — indications and mechanisms in cardiovascular diseases. Autoimmun Rev 7 (2008), 445–452.
213. [213] McNamara, D.M., Rosenblum, W.D., Janosko, K.M., Trost, M.K., Villaneuva, F.S., Demetris, A.J., et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 95 (1997), 2476–2478.
214. [214] Gullestad, L., Aass, H., Fjeld, J.G., Wikeby, L., Andreassen, A.K., Ihlen, H., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 (2001), 220–225.
215. [215] McNamara, D.M., Holubkov, R., Starling, R.C., Dec, G.W., Loh, E., Torre-Amione, G., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103 (2001), 2254–2259.
216. [216] Larsson, L., Mobini, R., Aukrust, P., Gullestad, L., Wallukat, G., Waagstein, F., et al. Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody. Autoimmunity 37 (2004), 489–493.
217. [217] Maisch, B., Pankuweit, S., Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives. Heart Fail Rev 18 (2013), 761–795.
218. [218] Drucker, N.A., Colan, S.D., Lewis, A.B., Beiser, A.S., Wessel, D.L., Takahashi, M., et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89 (1994), 252–257.
219. [219] Kishimoto, C., Shioji, K., Kinoshita, M., Iwase, T., Tamaki, S., Fujii, M., et al. Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress. Int J Cardiol 91 (2003), 173–178.
220. [220] Isogai, T., Yasunaga, H., Matsui, H., Tanaka, H., Horiguchi, H., Fushimi, K., Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses. J Card Fail 21 (2015), 391–397.
221. [221] Klugman, D., Berger, J.T., Sable, C.A., He, J., Khandelwal, S.G., Slonim, A.D., Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol 31 (2010), 222–228.
222. [222] Robinson, J., Hartling, L., Vandermeer, B., Klassen, T.P., Intravenous immunoglobulin for presumed viral myocarditis in children and adults. Cochrane Database Syst Rev, 5, 2015, CD004370.
223. [223] Olivieri, B.P., Vasconcellos, R., Nóbrega, A., Minoprio, P., Kaveri, S.V., Araújo-Jorge, T.C., Intravenous immunoglobulin increases survival time in the acute phase of experimental Chagas disease. Parasite Immunol 32 (2010), 464–469.
224. [224] Bozkurt, B., Villaneuva, F.S., Holubkov, R., Tokarczyk, T., Alvarez, R.J. Jr., MacGowan, G.A., et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 34 (1999), 177–180.
225. [225] Pescovitz, M.D., Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6 (2006), 859–866.
226. [226] Sanz, I., Indications of Rituximab in autoimmune diseases. Drug Discov Today Ther Strateg 6 (2009), 13–19.
227. [227] Erdei, A., Paragh, G., Kovacs, P., Karanyi, Z., Berenyi, E., Galuska, L., et al. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves’ orbitopathy: a five-year follow-up study. Autoimmunity 47 (2014), 548–555.
228. [228] Stan, M.N., Garrity, J.A., Carranza Leon, B.G., Prabin, T., Bradley, E.A., Bahn, R.S., Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 100 (2015), 432–441.
229. [229] Jahns, R., Jahns, V., Lohse, M., Palm, D., Means for the inhibition of anti-1-adrenergic receptor antibodies. [WO 2006/103101 A2], 2005.
230. [230] Münch, G., Boivin-Jahns, V., Holthoff, H.P., Adler, K., Lappo, M., Truöl, S., et al. Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-β1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail 14 (2012), 1230–1239 [Erratum in: Eur J Heart Fail 2013;15:478. Dosage error in article text].
231. [231] Corimmun GmbH, Safety, pharmacokinetic and pharmacodynamic study of COR-1, an anti-β1 receptor antibody cyclopeptide (COR-1-01). https://clinicaltrials.gov/show/NCT01043146, 2010.
232. [232] Janssen Research & Development, LLC, To assess the pharmacokinetics and safety of single doses of JNJ-54452840 in healthy Japanese and Caucasian participants. https://clinicaltrials.gov/show/NCT01043146, 2013.
233. [233] Keefe, A.D., Pai, S., Ellington, A., Aptamers as therapeutics. Nat Rev Drug Discov 9 (2010), 537–550.
234. [234] Bruno, J.G., Predicting the uncertain future of aptamer-based diagnostics and therapeutics. Molecules 20 (2015), 6866–6887.
235. [235] Dahmen, C., Haberland, A., Kage, A., Schimke, I., Wallukat, G., Aptamers that inhibit interaction between antibody and 2nd extracellular loop of human beta-1-adrenergic receptor. PCT/EP2011/060572, WO2012000889 A1, 2011.
236. [236] Haberland, A., Wallukat, G., Berg, S., Schulz, A.M., Freyse, E.J., Vetter, R., et al. Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats. Mol Cell Biochem 393 (2014), 177–180.
237. [237] Schimke I, Haberland A, Wallukat G (2012) Use of aptamers in therapy and/or diagnosis of autoimmune diseases. [EP2497828A1, WO2012119938A2], 2012.
238. [238] Haberland, A., Holtzhauer, M., Schlichtiger, A., Bartel, S., Schimke, I., Müller, J., Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors. Eur J Pharmacol 789 (2016 Oct 15), 37–45, 10.1016/j.ejphar.2016.06.061.
239. [239] ClinicalTrial.gov Identifier NCT02955420.
240. [240] Marquis, J.K., Grindel, J.M., Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther 2 (2000), 258–263.